Arch Therapeutics, Inc. (ARTH)
- GlobeNewswire
Arch Therapeutics Provides Year End Operational Update
Continued Strong Trends in Orders and Paid ClaimsFRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”). During its fourth fiscal quarter, the Company
- GlobeNewswire
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
AC5® Advanced Wound System to be Featured in the Hands-On Skills Lab for Clinicians and a Clinical Case Poster Demonstrating Utility in Treatment of Venous Leg UlcersFRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2023 Symposium on Advanc
- GlobeNewswire
Arch Therapeutics Provides AC5® Commercialization Update
Orders and Paid Claims Increasing Since Rollout of Reimbursement CodeFRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5® Advanced Wound System. Since the Centers for Medicare and Medicaid Services (“CMS”) established A2020, a Level II Healthcare Common Procedure Codi
